The estimated Net Worth of Margo Heath Chiozzi is at least $4.89 million dollars as of 3 June 2024. Margo Chiozzi owns over 64,658 units of Celldex Therapeutics stock worth over $2,987,753 and over the last 7 years he sold CLDX stock worth over $1,319,156. In addition, he makes $580,206 as Senior Vice President - Regulatory Affairs at Celldex Therapeutics.
Margo has made over 6 trades of the Celldex Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 64,658 units of CLDX stock worth $662,745 on 3 June 2024.
The largest trade he's ever made was exercising 64,658 units of Celldex Therapeutics stock on 3 June 2024 worth over $662,745. On average, Margo trades about 8,256 units every 104 days since 2017. As of 3 June 2024 he still owns at least 71,752 units of Celldex Therapeutics stock.
You can see the complete history of Margo Chiozzi stock trades at the bottom of the page.
Dr. Margo Heath-Chiozzi M.D. serves as Senior Vice President - Regulatory Affairs of the Company. Previously from 2003 until September 2017, Dr. Heath-Chiozzi served in roles of increasing responsibility at Bristol-Myers Squibb Company including Executive Director, Global Regulatory Sciences; Vice President, Global Regulatory Strategy; and Vice President, Global Submissions and Regulatory Policy. Prior to that, from 1995 to 2003, Dr. Heath-Chiozzi served in roles of increasing responsibility at Abbott Laboratories, including Medical Director, Pharmacogenetics; Senior Director, Global Marketed Product Development and Outcomes Research; and Global Project Head, Abbott/Millennium Obesity/Diabetes Alliance. Before joining Abbott, she was appointed to the University of Hawaii John A. Burns School of Medicine, where she served as Assistant Professor, and was concurrently Director of the HIV Research Clinical at the Queen's Medical Center as well as Director of the Women's Immunology Clinical at the Kapiolani Medical Center for Women and Children, in Honolulu. Dr. Heath-Chiozzi received her B.S. and M.D. from the University of Utah. She received further medical training in internal medicine at Duke University and completed fellowships in infectious disease at Brigham & Women's Hospital and Dana-Farber Cancer Institute in Boston.
As the Senior Vice President - Regulatory Affairs of Celldex Therapeutics, the total compensation of Margo Chiozzi at Celldex Therapeutics is $580,206. There are 6 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.
Margo Chiozzi is 63, he's been the Senior Vice President - Regulatory Affairs of Celldex Therapeutics since 2017. There are 11 older and 13 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
Margo's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil et Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: